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Abstract
Activation of the RET gene by chromosomal rearrangements generating RET/PTC oncogenes is a frequent, early, and
causative event in papillary thyroid carcinoma (PTC). We have previously shown that, in human primary thyrocytes,
RET/PTC1 induces a transcriptional program including the MET proto-oncogene. In PTCs, β-catenin is frequently mis-
located to the cytoplasm nucleus. We investigated the interplay between Ret/ptc1 signaling and Met in regulating the
proinvasive phenotype and β-catenin localization in cellular models of human PTC. Here, we show that Met protein is
expressed and is constitutively active in human thyrocytes exogenously expressing RET/PTC1 as well as a mutant
(Y451F) devoid of the main Ret/ptc1 multidocking site. Both in transformed thyrocytes and in the human PTC cell
line TPC-1, Ret/ptc1-Y451–dependent signaling andMet cooperated to promote a proinvasive phenotype. Accordingly,
gene/functional silencing of either RET/PTC1 or MET abrogated early branching morphogenesis in TPC-1 cells. The
same effect was obtained by blocking the common downstream effector Akt. Y451 of Ret/ptc1 was required to
promote proliferation and nuclear translocation of β-catenin, suggesting that these oncogene-driven effects are
Met-independent. Pharmacologic inhibition of Ret/ptc1 and Met tyrosine kinases by the multitarget small molecule
RPI-1 blocked cell proliferation and invasive ability and dislocated β-catenin from the nucleus. Altogether, these results
support that Ret/ptc1 cross talkswithMet at transcriptional and signaling levels and promotes β-catenin transcriptional
activity to drive thyrocyte neoplastic transformation. Such molecular network, promoting disease initiation and acqui-
sition of a proinvasive phenotype, highlights new options to design multitarget therapeutic strategies for PTCs.
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Introduction
Papillary thyroid carcinoma (PTC), the most prevalent neoplastic
disease of the thyroid gland, presents several morphologic variants,
usually characterized by slow growth and clinical indolence, although
aggressive forms associated with local and distant invasion can occur
[1]. Four alternative genetic lesions have been identified as driving on-
cogenic alterations in PTCs: rearrangements of RET or TRK genes
and activating mutations of BRAF or RAS [2].
The RET proto-oncogene, encoding the receptor tyrosine kinase
for the glial cell line–derived neurotrophic factor family of peptides,
plays a crucial role in transducing growth and differentiation signals
in tissues derived from the neural crest [3]. RET oncogenic activation
by somatic chromosomal rearrangement is a specific event in PTC
tumorigenesis. The resulting RET/PTC oncogenes are among the
most frequent genetic alterations in this pathology. Twelve different
fusion partner genes have been identified so far with the most prev-
alent variant being RET/PTC1 (60-70%) derived from the fusion of
RET with the H4 (D10S170) gene. The products of the resulting
rearranged genes are constitutively active oncoproteins that have lost
the transmembrane domain [1,4]. Phosphorylation of the residue
corresponding to tyrosine 1062 in proto-RET is essential for the re-
cruitment of several adaptor and signaling proteins, thus playing a
crucial role in the transforming effects of Ret oncoproteins including
increased cell proliferation, migration, and altered adhesion [2]. Ex-
perimental evidence supports RET/PTC rearrangements as causative
factors in the pathogenesis of PTC. Exogenous expression of RET/
PTCs in human thyrocytes has been shown to stimulate their prolif-
eration [5,6] and to induce typical changes in nuclear envelope and
chromatin, which are diagnostic for PTC [7]. The ability of RET/
PTCs to initiate carcinogenesis has been confirmed in transgenic
mice [8]. Nevertheless, other alterations of signaling through growth
factors and their receptors, cell cycle regulators, and adhesion mole-
cules seem to contribute to thyroid neoplasia progression [1].
Owing to the specialized structure of the thyroid, the epithelial
mechanisms of cell-cell adhesion play an important role in tissue
integrity. In the normal thyroid, the E-cadherin/catenins system con-
stitutes the main epithelial adhesion complex [9]. It has been sug-
gested that loss of E-cadherin and altered expression/localization of
β-catenin, which have been described in subsets of thyroid carci-
nomas [10–12], may represent tumor progression factors. Indeed,
deregulation of this system, which promotes the transcriptional func-
tion of β-catenin, has been involved in the development and pro-
gression of several malignancies [13]. Phosphorylation is a major
mechanism regulating the dual function of β-catenin. In particular,
tyrosine phosphorylation by different protein kinases switches the
function of β-catenin from adhesion to transcription [14].
The tyrosine kinase receptor for hepatocyte growth factor (HGF)
Met is overexpressed in most PTCs, whereas it is not present in the
normal thyroid follicle [15]. Experimental and clinical data point to
Met deregulation as a key event in tumor invasive growth and met-
astatic spreading [16]. In particular, in thyroid cancer, HGF-Met
signaling modulates cell motility and invasiveness and promotes
angiogenesis [17,18]. Met transcription in thyroid carcinomas is
thought to be regulated as an effect secondary to the activation of
driving oncogenes such as RET, HRAS, and BRAF [19,20].
We previously demonstrated that exogenous expression of RET/
PTC1 in human primary thyrocytes activates a complex transcrip-
tional program leading to the up-regulation of several genes involved
in inflammation, invasion, and matrix remodeling, including MET
[6]. In the present study, we investigated the respective contribution
of Ret/ptc1 and Met in the proinvasive phenotype and β-catenin dys-
regulation in PTC. We addressed this issue by using the previously
described in vitro model of human thyroid carcinogenesis [6] and the
human PTC cell line, TPC-1, endogenously expressing the RET/
PTC1 oncogene. Genotypic/phenotypic and biochemical/biological
correlations were investigated either by selective silencing of RET/
PTC1 and MET or by pharmacological inhibition of both tyrosine
kinases using the multitarget inhibitor RPI-1 [21,22]. The results indi-
cated that RET/PTC1 induces Met protein expression and β-catenin
nuclear translocation in human follicular thyroid cells, the first effect
being independent from the Ret/ptc1 crucial multidocking site Y451.
In addition, a functional cooperation between Ret/ptc1 and Met signal-
ing in the promotion of cell invasive ability is shown. These findings
support a direct causative relationship between a specific oncogene,
RET/PTC1, and two other alterations, Met expression and β-catenin
mislocation, implicated in the pathogenesis of PTC.
Materials and Methods
Chemicals and Antibodies
The synthesis and the chemical structure of RPI-1 (1,3-dihydro-
5,6-dimethoxy-3-[(4-hydroxyphenyl) methylene]-H -indol-2-one)
were reported previously (Cpd1) [23]. The drug dissolved in di-
methylsulfoxide was further diluted in cell culture medium (final sol-
vent concentration, 0.5%). Only where indicated, HGF (Sigma, St.
Louis, MO) was added to the medium at 20 ng/ml.
Mouse monoclonal antibodies used were as follows: antiphospho-
tyrosine, clone 4G10, from Upstate Biotechnology (Lake Placid, NY);
anti–PKBα/Akt from Transduction Laboratories (Lexington, KY);
anti–β-tubulin from Sigma; anti–β-catenin from Abcam (Cambridge,
UK); and anti–cyclin D1 (R-124) and anti–p-β-catenin (1B11) from
Santa Cruz Biotechnology (Santa Cruz, CA).
Rabbit polyclonal antibodies used were as follows: anti–phospho-
Ret (Y1062), anti-Met (C-12), and anti-Ret (C-19) from Santa Cruz
Biotechnology; anti–phospho-Met (Y1234/Y1235) from Upstate
Biotechnology; anti–phospho-Akt (S473) and anti–phospho-Ret
(Y905) from Cell Signaling (Beverly, MA); anti–β-catenin and anti-
actin from Sigma; anti-Ret recognizing a C-terminal sequence (aa
1000-1014) [24]; and anti–phospho β-catenin (Y142) from Abcam.
Cell Culture and Proliferation Assay
The human PTC cell line TPC-1 and the Nthy-ori 3-1 cell line
derived from human thyroid follicular epithelium were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) and RPMI (Cambrex
Bio Science, Walkerville, MD), respectively, supplemented with
10% fetal bovine serum. Establishment of human primary thyrocytes
and infection with retroviral vectors containing RET/PTC1 or RET/
PTC1-Y451F were previously described [6]. Parental (normal human
thyrocytes, NTs) and infected thyrocytes (RTPC and RTPC-YF)
were cultured in medium containing DMEM, F12, and MDCB 104
(at a ratio of 2:1:1; Invitrogen, Carlsbad, CA) and supplemented with
10% fetal bovine serum. Mouse fibroblasts NIH3T3 transfected with
RET/PTC1 (NIH3T3PTC1) and parental NIH3T3 cells were main-
tained inDMEMcontaining 5% and 10% calf serum (Colorado Serum
Company, Denver, CO), respectively, in a 10% CO2 atmosphere.
For cell growth assays, cells were plated in 96-well plates and, the
day after seeding, were exposed to solvent or different concentrations
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of RPI-1 for 72 or 144 hours as indicated. Then, cells were subjected
to the sulforhodamine B (SRB) colorimetric assay as previously de-
scribed [21]. Drug concentrations able to inhibit cell proliferation by
50% (IC50) were calculated from dose-response curves.
Biochemical Analyses
When indicated, cells were treated with different concentrations of
RPI-1 the day after seeding. To study HGF-induced effects in the
presence of RPI-1, TPC-1 cells were serum-starved for 24 hours,
treated with the drug for 18 hours, and then stimulated with HGF
for 10 minutes before lysis. Cells were processed for immunoprecipi-
tation or total protein extraction and were then examined by Western
blot analysis as previously described [25].
Early Branching Morphogenesis Assay
Formation of cellular networks was assayed in 48-well plates lay-
ered with artificial extracellular matrix (Matrigel; BD Biosciences,
San Jose, CA). Cells were suspended in serum-free medium and
overlaid on the gelled Matrigel. When indicated, medium was sup-
plemented with 20 ng/ml HGF. In experiments performed in the
presence of RPI-1, cells were pretreated with different concentrations
of the drug for 24 hours and then transferred in drug-added medium
onto the Matrigel layer. After incubating at 37°C for 4 hours,
branches were photographed with a digital camera. Quantification
of branches was performed by measuring the total length of struc-
tures per field by the Image Analysis System software (Delta System,
Rome, Italy). Data are reported as percentage of control ± SD.
Cell Migration and Scatter Assay
For the migration assay, cells were seeded in the upper side of
Transwell chambers (Costar; Corning Incorporated, Corning, NY)
in serum-free medium. To evaluate cell migration in the presence
of RPI-1, cells were pretreated with the drug in complete medium
for 24 hours. The same drug concentration used for pretreatment
was then added in both upper and lower chambers. To assess HGF-
induced cell migration, the growth factor was added in the lower
chamber. After 5 hours of incubation at 37°C, migrated cells were
fixed in 95% ethanol, stained with a solution of 2% crystal violet in
70% ethanol and counted under an inverted microscope.
For the scatter assay, cells were seeded at a low density in complete
medium to allow growing as islets. The day after, cells were serum-
starved for 24 hours. Then, cells were treated with RPI-1 in the pres-
ence or absence of HGF for 18 hours before observation under a
phase-contrast microscope equipped with photo camera.
Antibody Intracellular Transfer
Cells were subjected to protein delivery assay using PULSin (PolyPlus
Transfection, Illkirch, France) as a delivery reagent for specific anti-
bodies or aspecific rabbit IgG (Sigma) according to the manufac-
turer’s instructions. After 4 hours of incubation with the PULSin/
antibody mixture at 37°C, the antibody transfer solution was re-
moved and replaced with fresh complete medium. Cells were used
for the tubulogenesis assay 24 hours later, as previously described.
RNA Interference
To silenceRET/PTC1, theHs-RET-9-HP–validated siRNA (100 nM)
fromQiagen (Santa Clarita, CA) was used.METsilencing was induced
using the MET2 and MET5 specific 21 nucleotides (200 nM) previ-
ously described [26] (Ambion, Austin, TX). Negative control siRNA
(AllStars) were from Qiagen. The oligonucleotides were transfected
into the cells using the SiImporter reagent (Upstate Biotechnology)
in serum-free medium according to the manufacturer’s instructions.
Cells were incubated for 6 hours before serum addition and were
then further incubated for 3 or 5 days to downmodulate Met or Ret/
ptc1 protein, respectively. Cells were then lysed or subjected to biolog-
ical assays.
Indirect Immunofluorescence Staining of β-Catenin
Cells were fixed with 3% paraformaldehyde in PBS for 15 min-
utes, then permeabilized in 100% cold methanol for 1 minute,
and washed in PBS. After blocking in 1% BSA in PBS for 1 hour,
cells were incubated with anti–β-catenin antibody (1:2000; Sigma)
for 1 hour. Alexa 488–conjugated goat antirabbit IgG-FITC (Mo-
lecular Probes, Inc, Eugene, OR) was used as a secondary antibody.
After washing, nuclei were counterstained with Hoechst 33341 (Sigma),
and slides were examined by a fluorescent microscope equipped with
a digital camera.
Statistical Analysis
Statistical analyses were performed using Student’s 2-tailed t test. A
value of P < .05 was considered statistically significant.
Results
RET/PTC1 Oncogene Specifically Induces Met Protein
Expression in Human Thyrocytes Independently from Its
Crucial Multidocking Site Y451
We used human NTs and thyrocytes infected with retroviral vec-
tor expressing RET/PTC1 (RPTC), or the RET/PTC1-Y451F mutant
(RPTC-YF), as a model for PTC [6] to investigate the cross talk be-
tween Ret/ptc1 and Met kinases and their role in thyroid carcinogen-
esis. We confirmed the expression of Met in Ret/ptc1–expressing
thyrocytes at the protein level (Figure 1A). Met expression in both in-
fected thyrocytes was similar to that detected in the Ret/ptc1–positive
PTC cell line TPC-1, whereas it was absent in NT cells. Moreover,
Western blot analysis indicated that Met protein expression was in-
dependent from the Ret/ptc1 Y451–mediated signaling because both
RPTC and RPTC-YF cells showed similar levels of the protein (Fig-
ure 1A). The presence of serum in the medium did not affect Met
expression. The analysis of the phosphorylation status of Met immu-
noprecipitated from serum-starved cells revealed that the receptor
tyrosine kinase was constitutively active in RPTC and RPTC-YF
thyrocytes (Figure 1B) and in TPC-1 cells (Figure 3A). At variance,
stable expression of RET/PTC1 oncogene neither induced Met ex-
pression in NIH3T3 murine fibroblasts nor modulated Met endog-
enous levels in HeLa human cervical cancer cells (not shown), thus
suggesting a cellular-specific RET/PTC1 effect in thyrocytes.
Met Cooperates with Ret/ptc1 to Confer Invasive But Not
Proliferative Ability to NTs
We examined Ret/ptc1–induced biological effects including invasive-
related cell abilities, such as migration and early branching morpho-
genesis, and the proliferative capability, in human thyrocytes.
Morphogenic properties of thyrocytes were evaluated by an early
tubulogenesis assay testing the cells’ ability to aggregate and form
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branches in a few hours when cultured in Matrigel in the absence
of serum [27]. RPTC cells, endowed with fully functional Ret/ptc1
oncoprotein, spontaneously formed complex branched structures,
already evident 4 hours after seeding (Figure 1C ). In contrast, NT
(not shown) and RPTC-YF cells (Figure 1C ) did not form branched
structures even after a more prolonged period. After 7 hours of incu-
bation, morphogenesis of RPTC-YF cells was stimulated in the pres-
ence of HGF. These results indicated that in RET/PTC1–transformed
thyrocytes Y451-mediated signaling is required in the events leading
to branching morphogenesis and suggested that Met, in a hyperacti-
vated state, may contribute to the morphogenic phenotype of trans-
formed thyrocytes.
In a migration assay, NT displayed only marginal spontaneous cell
motility, whereas RPTC thyrocytes showed a significant increase in
motile capacity similar to that of TPC-1 cells (Figure 1D). Y451F
mutant thyrocytes showed a low intermediate motility that could be
further stimulated by exogenous HGF by nearly 20% (not shown).
These findings suggested that both Ret/ptc1 and Met signaling path-
ways contributed to confer motile capacity to human thyrocytes. In
addition, such property seemed not exclusively dependent on the
Ret oncoprotein Y451 multidocking site.
We previously showed that the exogenous expression of RET/
PTC1 conferred a proliferative advantage to human thyroid follicular
cells requiring a functional Y451 multidocking site [6]. Because Met
protein was induced in both RPTC and RPTC-YF thyrocytes (Fig-
ure 1A), our present data suggested that Met did not influence the
growth of human thyrocytes. In agreement, HGF did not stimulate
proliferation of TPC-1 cells (not shown) and it was reported not to
affect the survival of Met-positive cell lines established from thyroid
carcinomas [28]. Consistently, treatment with the tyrosine kinase in-
hibitor RPI-1, targeting both Ret/ptc1 and Met [21,22], abrogated
the proliferative advantage of RPTC thyrocytes (Figure 2A), whereas
it only marginally affected the low proliferative capacity of parental
NT and RPTC-YF cells (not shown). The growth of either RPTC
thyrocytes or established tumor cells (TPC-1) harboring fully func-
tional RET/PTC1 was inhibited by a 72-hour treatment with RPI-1
in a similar dose-dependent way (Figure 2B). In fact, RPI-1 showed
a comparable IC50 in RPTC and TPC-1 cells (5.4 ± 0.4 and 6.3 ±
Figure 1. Met expression/activation and morphogenic/motogenic phenotype induced by ectopic expression of RET/PTC1 oncogene in
human thyrocytes. (A) Western blot analysis of Met protein expression in thyrocytes uninfected (NT), infected with RET/PTC1 (RPTC), or
the RET/PTC1-Y451Fmutant (RPTC-YF) and in the RET/PTC1–positive PTC cell line TPC-1. Whole cell lysates were obtained after 24 hours
in complete (+) or in serum-free (−) medium. Antitubulin blot is shown as a control for loading. (B) Met tyrosine phosphorylation in
RPTC-YF and RPTC cells. Met protein was immunoprecipitated from cells serum-starved for 24 hours, and its phosphorylation was
analyzed by Western blot analysis using a pan anti–ptyrosine antibody (pY). The filter was reprobed with anti-Met antibody after strip-
ping. (C) Early tubulogenesis assay. Cells were seeded in Matrigel-coated wells in the absence of serum, with (+) or without (−) HGF.
Four hours after plating, extensive tubule networks were formed by RPTC thyrocytes. RPTC-YF cells formed branched cellular cords
after 7 hours of incubation only in the presence of HGF. Original magnification, ×400. (D) Spontaneous cell migration. Cells were sub-
jected to a migration assay in serum-free medium. Migrating cells were counted under a light microscope and reported as cell number
per field. Columns represent mean values ± SD of two independent experiments. **P < .005, ***P < .0005 versus NT.
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0.2 μM, respectively), whereas more than a six-fold increase in IC50
was observed in parental NT and RPTC-YF thyrocytes and in the
thyroid follicular cell line Nthy-ori 3-1 (IC50 > 30 μM). The trans-
formed morphology of RPTC thyrocytes, characterized by increased
refraction and loss of cell contact inhibition, was reverted by RPI-1
treatment with the restoration of the flat contact–inhibited morphol-
ogy of the parental cells (Figure 2C ). In RPTC thyrocytes, Ret/ptc1
inhibition by RPI-1 in the range of concentrations affecting both cell
proliferation and morphology was confirmed by the abrogation of
Y451 phosphorylation (Figure 2D). Activation of Akt, previously
shown to be induced by RET/PTC1 expression in thyrocytes [6], was
also inhibited by RPI-1 treatment in a dose-dependent way.
TPC-1 Cell Morphogenic Phenotype Depends on Both Met and
Ret/ptc1 Signaling
We investigated the role of Met and Ret/ptc1 and the effects of
kinase inhibition in the regulation of the motile phenotype in the
PTC cellular context.
In serum-starved TPC-1 cells, tyrosine phosphorylation of Met
was indicative of the receptor constitutive activation (Figure 3A).
On HGF addition, Met and Akt phosphorylation were markedly en-
hanced, indicating that the receptor tyrosine kinase retains biochem-
ical responsiveness to its physiological ligand. Cell pretreatment with
RPI-1 prevented HGF-induced activation of both Met and Akt.
The biological responsiveness of TPC-1 cells to HGF was exam-
ined by functional assays. In a migration assay, cells stimulated with
HGF doubled their basal migratory ability (Figure 3B). Such ligand-
induced cell motility was prevented by 24 hours of pretreatment with
15 μM RPI-1, whereas higher doses of the drug also inhibited the
spontaneous cell motility (not shown).
The HGF-dependent motogenic properties of TPC-1 cells were
further evaluated in a scatter assay in which cell response to the
growth factor comprises an initial cell dissociation, involving cyto-
skeletal reorganization and loss of intercellular junctions, followed by
active migration [27]. Whereas control unstimulated cells appeared
packed in islands with tight cell-to-cell junctions (cell clusters),
Figure 2. Effects of RPI-1 on human primary thyrocytes and thyroid cell lines. (A) Abrogation of RET/PTC1 growth-promoting effect.
Uninfected thyrocytes (NT) or thyrocytes infected with RET/PTC1 (RPTC) or RET/PTC1-Y451F (YF) were treated with solvent (−) or with
the indicated concentrations of RPI-1 for 6 days. Cell density was measured by the SRB colorimetric assay and was expressed as optical
density (OD) at 550 nm (mean ± SD). One experiment representative of three is shown. (B) Cell growth inhibition. Primary thyrocytes
and thyroid cell lines (follicular epithelial Nthy-ori 3-1 and PTC TPC-1) were exposed to solvent or to different concentrations of RPI-1 for
72 hours. The drug antiproliferative effect was evaluated by the SRB assay. Representative dose-response curves are shown. (C) Re-
version of RET/PTC1–transformed morphologic phenotype. Normal human thyrocytes and RPTC thyrocytes were treated with 10 μM
RPI-1 for 48 hours and were then photographed under phase-contrast microscope. Original magnification, ×100. (D) Inhibition of Ret/
ptc1-Y451 and Akt-S473 phosphorylation. RPTC cells were exposed to solvent (−) or to the indicated concentrations of RPI-1 for 24 hours.
Western blot analysis of total protein extracts was performed with phospho-specific antibodies recognizing phosphorylated Y451 (pRet)
and S473 (pAkt) of Ret/ptc1 and Akt, respectively. The filter was then stripped and reprobed with the respective antiprotein antibodies.
Antiactin blot is shown as protein loading control.
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HGF addition to the culture medium caused loss of cell junctions and
cell dispersal throughout the culture dish (Figure 3C). In addition, cells
acquired a spindle-shaped morphology resembling a typical epithelial-
to-mesenchymal transition (EMT) [29]. Pretreatment with RPI-1 im-
paired this process, preserving most cell-to-cell contacts.
Because the previously described results suggested that both Ret/
ptc1 and Met play a role in the regulation of the motogenic pheno-
type of human transformed thyrocytes, we investigated the contribu-
tion of the single protein kinase on the morphogenic phenotype of
TPC-1 tumor cells using selective knockdown approaches. The RNA
interference technology was used to elucidate gene function in the
branching morphogenesis assay. Transfection with a specific RET
siRNA caused the down-regulation of the two Ret/ptc1 isoform pro-
teins (Figure 4A), which was reflected in a high reduction of their
overall tyrosine phosphorylation (not shown). No downmodulation
of Met levels was observed. RET/PTC1 knockdown heavily impaired
the morphogenic activity of TPC-1 cells (Figure 4A). In a comple-
mentary experiment, transfection with two different MET siRNA
caused a marked reduction of both the precursor and the mature form
of the receptor without affecting Ret/ptc1 expression (Figure 4B).
Again, the spontaneous ability of TPC-1 cells to form branched struc-
tures seemed significantly impaired (Figure 4B).
The protein delivery technique was used as an alternative approach
for disrupting Met or Ret/ptc1 signaling. TPC-1 cells were loaded
with antibodies recognizing the protein kinases phosphorylated at
the crucial tyrosine residues Ret/ptc1-Y451 and Met-Y1234/Y1235,
which regulate Ret/ptc1 signaling and Met kinase activity [2,30], re-
spectively. Both phospho-specific antibodies caused a significant re-
duction of the extension of branched structures formed by TPC-1
cells (Figure 4C ). In contrast, cells loaded with aspecific IgG or an
anti-Ret antibody recognizing phosphorylated Y294 (corresponding
to Y905 of proto-Ret) [2] formed a cellular network similar to that of
vehicle-treated cells. Furthermore, both approaches, affecting gene ex-
pression or kinase functions of Ret/ptc1 or Met, also inhibited TPC-1
cell motility in the migration assay (not shown). Thus, neither Ret/
ptc1 nor Met signaling alone seemed sufficient to confer efficient mor-
phogenic ability to thyroid cells.
Ret/ptc1 and Met Signaling Converge on PI3K/Akt
Pathway Which Is Critical for the Morphogenic
Phenotype of TPC-1 Cells
Because both Ret and Met are known activators of the Akt path-
way [2,30], which has been implicated in thyroid cancer invasion
[31], we supposed that Akt-dependent signaling could play a central
role in the control of PTC morphogenic phenotype. Indeed, phar-
macological inhibition of both Ret/ptc1 and Met in TPC-1 cells
by RPI-1 was associated with the dose-dependent reduction of Akt
activation (Figure 5A) and the loss of cells’ ability to form branched
structures in Matrigel (Figure 5B). Moreover, the selective knock-
down of RET/PTC1 or MET by RNA interference, already shown
to counteract the branching morphogenesis (Figure 4, A and B), also
reduced Akt activation (Figure 5C ).
To specifically address the relevance of Akt, we examined the effect
of selective inhibition of its signaling pathway in the branching mor-
phogenesis assay. TPC-1 cells loaded by the protein delivery technique
with an antibody recognizing the Akt activating phosphorylation at
S473 resulted in significant cell impairment to form branched struc-
tures (Figure 5D). These results thus confirmed that Akt may be a
critical downstream effector in the regulation of the PTC proinvasive
phenotype cooperatively activated by Ret/ptc1 and Met kinases.
Ret/ptc1 Induces Nuclear Translocation of β-Catenin in
Thyroid Follicular Cells
Next, we addressed the involvement of β-catenin in the RET/
PTC1–driven transformed phenotype. β-Catenin, a dual-function
protein involved in both cell adhesion and transcription, depending
on its cellular localization, has been found dysregulated in thyroid
cancer [12]. We examined the cellular distribution of this protein
in parental and RET/PTC1–infected thyrocytes. NT and RPTC-YF
thyrocytes presented a similar perinuclear/cytoplasmic immunostain-
ing of β-catenin (Figure 6A). In contrast, accumulation of β-catenin
in the nuclei was observed in RPTC thyrocytes suggesting that a
Figure 3. Biochemical and motogenic effects of HGF in TPC-1 cells.
(A) Activation of Met and Akt. Serum-starved cells were treated for
18 hours with solvent (−) or 15 μM RPI-1 (+) and then stimulated
with HGF for 10 minutes. Met was immunoprecipitated (IP), and
its tyrosine phosphorylation was examined by Western blot analy-
sis using a pan anti–ptyrosine antibody (pY). Arrows indicate the
Met mature form. Western blot analysis of Akt activation was per-
formed on whole cell lysates using an antibody recognizing Akt
phosphorylated at S473 (pAkt). Filters were stripped and reprobed
with anti-Akt and anti-actin antibodies. (B) Cell migration. Cells
were exposed to vehicle or to 15 μM RPI-1 for 24 hours and then
transferred in Transwell chambers in serum-free medium with or
without HGF. Migrated cells are reported as number of cells per
field. One experiment representative of three is shown. (C) Cell
scattering. Cells were seeded at a low density to allow growing
as islets and, 24 hours later, serum-starved and treated with vehicle
or 15 μM RPI-1, in the presence or absence of HGF, for 18 hours.
Representative images are shown. Original magnification, ×100.
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functional Ret/ptc1-Y451–mediated signaling could promote the
nuclear translocation of β-catenin. Consistent with a transcriptionally
active β-catenin in RPTC cells, cyclin D1, which is known as a β-
catenin target gene [13], was up-regulated at both the RNA1 and
protein levels (Figure 6A). Treatment with RPI-1 caused β-catenin
redistribution in RPTC cells, as evidenced by a diffuse cytoplasmic
staining of the protein (Figure 6A). Accordingly, in RPI-1–treated
RPTC cells, β-catenin phosphorylation at Y142, described as one
of the crucial events switching from the adhesive to the transcrip-
tional role of the protein [32,33], was reduced in a dose-dependent
way, and cyclin D1 was downmodulated (Figure 6A). Similar results
were obtained in TPC-1 cells, in which RPI-1 treatment caused a
marked redistribution of β-catenin with complete disappearance of
the protein from nuclei and gain of junctional protein at cell-to-cell
surface contacts without altering the overall level of the protein (Fig-
ure 6B). Moreover, according to an increased adhesion to the plastic
well, RPI-1–treated cells showed a more flattened and enlarged mor-
phology. Furthermore, drug treatment induced a marked inhibition
of β-catenin Y142 phosphorylation (Figure 6B). Although Met has
Figure 4. Effects of selective expression or signaling knockdown of Ret/ptc1 and Met on TPC-1 cell morphogenic phenotype. (A) RET/
PTC1 silencing by siRNA. Cells were treated with transfection reagent (V), a specific RET siRNA (siRET) or an aspecific RNA oligonucle-
otide (siAsp) for 5 days. Left: Ret/ptc1 protein downmodulation. Immunoblot analysis with the indicated antibodies was performed on
whole cell lysates. Center: Effect of RET/PTC1 silencing on cell morphogenic properties. Cells were subjected to early branching mor-
phogenesis assay in Matrigel. Right: Total length quantification of branched structures. (B) MET silencing by siRNA. Cells were treated
with transfection reagent (V), with one of two different MET-targeting siRNA (siMET2 or siMET5) or with an aspecific oligonucleotide
(siAsp) for 3 days. Left: Met protein downmodulation. Total cell lysates were analyzed by Western blot analysis with the indicated anti-
bodies. Center: Effect of MET silencing on cell morphogenic properties. Right: Total length quantification of branched structures. (C)
Effects of intracellular delivery of antibodies recognizing specific tyrosine phosphorylations of Ret or Met. Left: Cells loaded with protein
delivery reagent alone (V), with anti-p(Y1234/Y1235) Met (pMet), anti-pY451 Ret, anti-pY294 Ret antibody, or aspecific immunoglobulins
(IgG) for 24 hours, were subjected to the early branching morphogenesis assay. Right: Total length quantification of branched struc-
tures. Representative images are shown. Original magnification, ×400. **P < .005, ***P < .0005.
1ArrayExpress database: Accession No. E-MEXP-429.
16 RET/PTC1, Met and β-Catenin in PTC Pathogenesis Cassinelli et al. Neoplasia Vol. 11, No. 1, 2009
been indicated as one of the kinases phosphorylating β-catenin Y142
in other cellular contexts [32,33], in TPC-1 cells, Met stimulation
with HGF did not modulate the phosphorylation of this tyrosine res-
idue (not shown). Recently, another β-catenin tyrosine residue, Y654,
has been reported as phosphorylated by Ret receptor mutants in med-
ullary thyroid carcinoma models [34]. This tyrosine phosphorylation
of β-catenin was also abrogated by RPI-1 treatment (Figure 6B).
To confirm the ability of Ret/ptc1 to modulate β-catenin localiza-
tion independently of Met, we investigated β-catenin distribution
in a cellular context not expressing Met. To this aim, as most epithe-
lial cell lines express Met protein at variable levels, we used parental
and RET/PTC1 stably transfected NIH3T3 fibroblasts, both with
undetectable Met protein expression. Contrary to thyrocytes, Met
was not up-regulated by RET/PTC1 in murine fibroblasts. RET/
PTC1–transformed NIH3T3 cells indeed showed a prevalent nuclear
localization of β-catenin (Figure 6C). Treatment with RPI-1 restored
the membrane/focal adhesion pattern of β-catenin distribution typical
of the NIH3T3 parental cells. Consistently, RPI-1 treatment of RET/
PTC1–expressing fibroblasts abrogated the up-regulation of cyclin D1
induced by the oncogene (Figure 6C).
Next, to determine whether Ret/ptc1 could interact with β-catenin
in the context of PTC, we performed a coimmunoprecipitation exper-
iment in TPC-1 cells. Ret/ptc1 was indeed present in the β-catenin
immunoprecipitate from the PTC cells with the prevalence of the
p64 long isoform (Figure 6D). Similarly, Ret/ptc1 and β-catenin
were coimmunoprecipitated from NIH3T3 and human embryonic
kidney HEK293T cells exogenously expressing genomic RET/PTC1
or the single RET/PTC1 short isoform, respectively (not shown). In
RPI-1–treated TPC-1 cells, such association was reduced, whereas
overall levels of β-catenin and Ret/ptc1 proteins were unchanged
Figure 5. Effects of concomitant or selective inhibition of Ret/ptc1, Met, and Akt signaling on TPC-1 cell morphogenic phenotype. (A)
Inhibition of Akt activation by the Ret/Met tyrosine kinase inhibitor RPI-1. Cells were exposed to solvent (−) or to the indicated concen-
trations of RPI-1 for 24 hours. Whole cell lysates (WCL) were analyzed directly or subjected to Met immunoprecipitation (IP) and then
analyzed by Western blot analysis. Activation status of the three kinases was detected using antibodies recognizing phosphorylated Ret/
ptc1 Y451 (pRet), Met Y1234/Y1235 (pMet), or Akt S473 (pAkt). Blots were then stripped and reprobed with antibodies against the re-
spective proteins. (B) left: Inhibition of cell ability to form branched structures in Matrigel by a 24-hour treatment with RPI-1. Right: Total
length quantification of branched structures. (C) left: Inhibition of AKT activation in RET/PTC1– or MET-silenced cells. Western blot anal-
ysis was performed on total cell lysates obtained from cells exposed to RET siRNA (siRET) or MET siRNA (siMET2) for 5 or 3 days,
respectively. V indicates transfection reagent. (D) left: Inhibition of branching morphogenesis by anti-pS473 Akt antibody (pAkt) intracellular
delivery. V indicates protein delivery reagent; IgG, aspecific immunoglobulins. Right: Total length quantification of branched structures.
Representative images are shown. Original magnification, ×400. *P < .05, **P < .005.
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(Figure 6D). These results thus implicate a direct role of Ret/ptc1
in the regulation of β-catenin functions.
Discussion
In the present study, using two different models of PTC, the most
frequent thyroid carcinoma histotype, we show that: 1) RET/PTC1,
an oncogene specific of this thyroid cancer, induces Met protein ex-
pression independently from the Y451 Ret/ptc1 multidocking site;
2) Ret/ptc1 and Met signaling cooperate to confer a proinvasive phe-
notype to thyroid cells; and 3) independently from Met, Ret/ptc1 is
able to induce nuclear translocation of β-catenin. We obtained con-
sistent results in both primary NTs exogenously expressing RET/
PTC1 and the PTC cell line TPC-1, endogenously expressing the
same oncogene.
Met overexpression is a feature of most PTCs, whereas it is not pres-
ent in the normal thyroid follicular cells [17]. It is thus conceivable
that the driving molecular alterations occurring in PTC might de-
regulate Met expression [1]. Among these, RET rearrangements have
been described by us and others to enhance MET gene transcription
Figure 6. Effects of RET/PTC1 expression and RPI-1 treatment on β-catenin expression, tyrosine phosphorylation, and localization in
human follicular thyroid cells and murine NIH3T3 fibroblasts. (A) Left: Immunofluorescence analysis of β-catenin localization in parental
thyrocytes (NT) and RET/PTC1– (RPTC) or RET/PTC1-Y451F–infected (RPTC-YF) thyrocytes exposed to solvent or to 15 μMRPI-1 for 72 hours.
Nuclei were evidenced with Hoechst 3341 counterstaining. Photos were taken under a florescence microscope equipped with a digital
camera. Right top: β-Catenin and cyclin D1 cellular levels. Right bottom: Inhibition of β-catenin Y142 phosphorylation and cyclin D1 ex-
pression in RPI-1–treated RPTC thyrocytes. Whole cell lysates were analyzed by Western blot analysis using the indicated antibodies. Anti-
actin blots are shown as protein loading control. (B) Left: β-Catenin localization examined by indirect immunofluorescence in TPC-1 cells
treated with solvent or with 60 μM RPI-1 for 72 hours. Right: β-Catenin expression and phosphorylation at Y142 and Y654 revealed by
Western blot analysis on whole cell lysates. (C) Top: β-Catenin localization in RET/PTC1–transformed NIH3T3 cells (NIH3T3PTC-1) exposed
to solvent (control) or to RPI-1 for 72 hours evidenced by immunofluorescence. Bottom: Modulation of cyclin D1 expression. Whole cell
lysates from parental NIH3T3 or NIH3T3PTC1 cells exposed to solvent (−) or to 30 μM RPI-1 (+) were subjected to Western blot analysis. (D)
Inhibition of Ret/ptc1 coimmunoprecipitation with β-catenin in TPC-1 cells treated with RPI-1. Control cells (−) and cells treated with RPI-1
(+) as in B were processed for immunoprecipitation (IP) with a monoclonal anti–β-catenin antibody or used for total protein extraction
(WCL). Samples were subjected to Western blot analysis with the indicated antibodies. Arrows indicate the long and short Ret/ptc1 iso-
forms. Antitubulin or antiactin blots are shown as protein loading controls. Original magnification, ×500.
18 RET/PTC1, Met and β-Catenin in PTC Pathogenesis Cassinelli et al. Neoplasia Vol. 11, No. 1, 2009
[6,19]. Here, we show that Met protein is expressed at comparable
levels in TPC-1 cells and in thyrocytes expressing Ret/ptc1 or its
mutant Y451F corresponding to the Ret Y1062 residue, known to
play a crucial role in the activation of signaling pathways mediating
RET-transforming activity. Moreover, Met was constitutively tyrosine-
phosphorylated in RET/PTC1– and RET/PTC1-Y451F–expressing
thyroid cells, most probably because of overexpression-induced kinase
activation [16]. Regulation of Met expression by the RET oncogene
seemed specific of the thyroid environment because RET/PTC1 did
not affect Met expression in other cellular models such as NIH3T3
or HeLa cells. Regulation of Met expression by its GC-rich TATA-less
promoter is complex, involving several transcription factors, including
hypoxia-inducible factor 1, and microRNA [35,36]. Our results,
showing that RET/PTC1 and the mutant RET/PTC1-Y451F, devoid
of Ret multidocking site, elicit comparable expression of METmRNA
and protein, suggest that RET-activated RAS/ERK and PI3K/AKT
pathways are dispensable for Met induction [6]. The possible role of
other Ret/ptc1–triggered signaling pathways in this event remains to
be investigated and would shed light on thyroid environment–specific
Met regulation. In transformed thyrocytes, as well as in TPC-1 cells,
Met maintained its biochemical and biological responsiveness to HGF.
Thus, Met induction by RET/PTC1 seems to confer sensitivity to the
motogenic/morphogenic effects of HGF in thyrocytes. Notably, genes
up-regulated by fully functional RET/PTC1 in thyrocytes include the
urokinase-type plasminogen activator (uPA)/uPA receptor system [6],
which catalyze the proteolytic cleavage required by HGF to become an
active ligand for Met [37]. HGF/Met, in turn, play a role in the reg-
ulation of the uPA/uPA receptor expression and of the proteolytic net-
work important for cell acquisition of invasive potential [38]. These
findings therefore indicate the ability of Ret/ptc1 to activate directly,
or indirectly through Met, different pathways cooperating in the pro-
motion of thyroid cell transformation and proinvasive phenotype. Fur-
ther experiments are needed to assess whether Met expression is still
dependent on Ret/ptc1 expression in established PTC.
Not only the cross talk between Ret/ptc1 and Met receptor tyro-
sine kinases was demonstrated at transcriptional level but it was also
shown that their signaling converges on the activation of downstream
mediators, such as Akt. Our results support a crucial role for Akt-
mediated signaling in the acquisition of the invasive phenotype by
PTC cells. In fact: 1) either RET/PTC1 or MET silencing lowered
Akt phosphorylation; and 2) Ret/ptc1, Met, or Akt functional
knockdown abolished the cell morphogenic phenotype. Altogether,
these data suggest that hyperactivation of Akt is necessary to promote
such phenotype in thyroid cells. Notably, the relative migratory ca-
pability displayed by NT, RPTC-YF, and RPTC thyrocytes, as shown
in this article, seemed well correlated with the previously reported
respective levels of Akt activation [6]. The PI3K/Akt pathway plays
a nodal role in the cross talk of different growth factors and onco-
genic signaling cascades, integrin receptors, and small GTPases that
control cytoskeleton organization [39]. In different cellular contexts,
the regulation of cell motility by Met or Ret was shown to require
PI3K recruitment to the receptor tyrosine kinase and the subsequent
activation of Akt [40,41]. Although Akt activation has been corre-
lated with tumor invasion in thyroid carcinoma [31], its relationship
with Ret and Met activation in PTCs was not previously addressed.
In this study, we have also demonstrated that the pleiotropic effects
of RET/PTC1 in human follicular thyroid cells include β-catenin nu-
clear translocation. In fact, differently from parental and RET/PTC1-
Y451F mutant thyrocytes, RET/PTC1–expressing thyrocytes showed
a prevalent nuclear localization of β-catenin, associated with an in-
creased expression of its transcriptional target gene, cyclin D1. This
effect suggested a β-catenin functional switch from adhesive to tran-
scriptional activity. Accordingly, several well-known and putative β-
catenin target genes2 [13,42,43] are upmodulated by RET/PTC1,
but not by RET/PTC1-Y451F, in human thyrocytes [6]. Such genes
include CD44 and its ligand OPN, COX2, LEF1, JUN, EGR-1,
CCL2, CXCL8, MMP7, MMP10, and FN1.1 Nuclear mislocation
of β-catenin has been found in PTC samples, in particular, in poorly
differentiated and micro PTC [10,44]. The relative proliferative po-
tential of NT, RPTC-YF, and RPTC thyrocytes suggested a correla-
tion between β-catenin nuclear localization and proliferation. Indeed,
we observed that inhibition of the Wnt/β-catenin pathway in TPC-1
cells by the known inhibitor indomethacin [45] caused disappearance
of β-catenin from the nucleus and a marked cell growth inhibition
(data not shown), thus supporting such interpretation. Although ac-
tive Met has been shown able to induce β-catenin translocation to
the nucleus in other cellular contexts [46], we have found that in
thyrocytes this effect seemed to be driven by Ret/ptc1. β-Catenin
nuclear translocation, at variance with Met induction, was indeed
dependent on Ret/ptc1-Y451 signaling. In keeping with a Met-
independent effect, nuclear translocation of β-catenin was induced
by Ret/ptc1 even in NIH3T3 fibroblasts, not expressing detectable
Met protein. In fibroblasts, as well as in thyroid cells, inhibition of
Ret/ptc1 kinase activity by the small molecule RPI-1 restored β-
catenin distribution typical of parental cells. Moreover, an interaction
between Ret/ptc1 and β-catenin was supported by coimmunoprecip-
itation of the two proteins in RET/PTC1–positive cells. Notably, it
was recently demonstrated that transmembrane oncogenic forms of
Ret associated to multiple endocrine neoplasia activate β-catenin sig-
naling by direct interaction and phosphorylation at Y654 in medul-
lary thyroid carcinoma [34]. Here, we showed that inhibition of
Ret/ptc1 kinase activity in PTC cellular models was associated with
β-catenin dislocation from the nucleus and dephosphorylation at
Y654 as well as Y142, another tyrosine residue implicated in the regu-
lation of β-catenin cellular localization [32,33].
Alterations in cell adhesive properties and gain of a migratory phe-
notype have been associated with EMT [29,39]. This developmental
process whereby embryonic cells switch from a polarized, epithelial
phenotype to a highly motile, mesenchymal phenotype has been im-
plicated in carcinoma invasion. Indeed, our data are in keeping with
the emerging concept that molecular mechanisms that control cell
migration during embryological development, including EMT, may
be reactivated in invading thyroid cancer cells [47]. Noteworthy, a
cooperative cross talk between Ret and Met has also been suggested
during the renal embryonic development [48,49]. The exact role of
EMT-related signaling pathways in thyroid cancer cell invasion has
not been fully elucidated, although recognized thyroid oncogenes
such as RET/PTCs, BRAF, and RAS seem to be involved in the reg-
ulation of this process [47]. Molecular markers of EMT, including
metalloproteases and the couples of ligand/receptors osteopontin/
CD44 and CXCL12/CXCR4 have been associated with RET/PTC1
expression in thyroid cells [6,50]. The present study shows the early
induction of additional recognized EMTmarkers, that is, overexpres-
sion of an active Met protein and β-catenin translocation, in asso-
ciation with the acquisition of in vitro phenotypic markers such as
2http://www.stanford.edu/~rnusse/pathways/targets.html.
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increased capacity for migration and extracellular matrix invasion.
Furthermore, as discussed, our data support a crucial role for Akt, a
well-recognized mediator of EMT [39], in the acquisition of the mor-
phogenic phenotype by PTC cells.
RET/PTC1 has already been shown to activate a proinflammatory
program in NTs, thus providing a link between the oncogene and
inflammation, a peritumoral reaction frequently observed in PTCs
[1,6,51]. The up-regulation of genes implicated in invasion, includ-
ing several metalloproteases and chemokines, also suggested a direct
link with locoregional spread, another pathologic characteristic of
PTCs and peculiar of RET/PTC1–positive cases [52]. Our present
results, demonstrating an early activation of invasion-related mole-
cules, such as Met, β-catenin, and Akt, in cooperation with the
Ret/ptc1 oncoprotein, further contribute to provide a rational molec-
ular basis for understanding clinical distinguishing features of PTCs
and may have therapeutic implications. Effective therapies for meta-
static thyroid cancers are not available, thus indicating the need for
alternative therapies. Preclinical studies by other groups and ours
have already demonstrated the possible role of RET oncoproteins
as therapeutic targets [4,25], and clinical trials are presently evaluat-
ing the efficacy of small molecule Ret inhibitors on thyroid cancers.3
The present study indicates Met tyrosine kinase as an additional tar-
get in PTC treatments. The role of Met as a therapeutic target has
been extensively documented in preclinical studies [53] and is cur-
rently under evaluation in the clinical setting with Met-targeting ty-
rosine kinase inhibitors.3 Here, we show that concomitant inhibition
of PTC cell growth and migration/invasion can be achieved even by a
single small molecule inhibitor such as the Ret/Met inhibitor RPI-1.
In addition, a marked inhibitory effect on the secretion of chemo-
kines such as CCL2 (unpublished) also suggests an impairment of
oncogene-activated inflammatory program by drug treatment.
Altogether, our results suggest that Ret/ptc1 induces and cooper-
atively interacts with Met signaling and promotes β-catenin tran-
scriptional activity to drive thyrocyte neoplastic transformation.
Such molecular network highlights new options to design multitarget
therapeutic strategies for PTCs.
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